ME02188B - Mali molekuli koji sadrže boron kao antiinflamatorni agensi - Google Patents
Mali molekuli koji sadrže boron kao antiinflamatorni agensiInfo
- Publication number
- ME02188B ME02188B MEP-2015-97A MEP9715A ME02188B ME 02188 B ME02188 B ME 02188B ME P9715 A MEP9715 A ME P9715A ME 02188 B ME02188 B ME 02188B
- Authority
- ME
- Montenegro
- Prior art keywords
- disease
- pharmaceutical formulation
- formulation according
- prevention
- compound
- Prior art date
Links
- 229940121363 anti-inflammatory agent Drugs 0.000 title claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 title claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title 1
- 229910052796 boron Inorganic materials 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 150000001875 compounds Chemical class 0.000 claims 16
- 230000002265 prevention Effects 0.000 claims 12
- 230000000699 topical effect Effects 0.000 claims 11
- 201000004624 Dermatitis Diseases 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 206010012438 Dermatitis atopic Diseases 0.000 claims 5
- 201000004681 Psoriasis Diseases 0.000 claims 5
- 201000008937 atopic dermatitis Diseases 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 5
- 208000017169 kidney disease Diseases 0.000 claims 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 206010012442 Dermatitis contact Diseases 0.000 claims 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 208000019693 Lung disease Diseases 0.000 claims 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 208000010247 contact dermatitis Diseases 0.000 claims 4
- 208000010643 digestive system disease Diseases 0.000 claims 4
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 4
- 208000019423 liver disease Diseases 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 3
- 208000003017 Aortic Valve Stenosis Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000027496 Behcet disease Diseases 0.000 claims 3
- 206010006895 Cachexia Diseases 0.000 claims 3
- 206010063094 Cerebral malaria Diseases 0.000 claims 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 3
- 208000001640 Fibromyalgia Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010024229 Leprosy Diseases 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 3
- 206010033645 Pancreatitis Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 208000006011 Stroke Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000007502 anemia Diseases 0.000 claims 3
- 206010002906 aortic stenosis Diseases 0.000 claims 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 208000035474 group of disease Diseases 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 150000008064 anhydrides Chemical class 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000010758 granulomatous inflammation Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77453206P | 2006-02-16 | 2006-02-16 | |
| US82388806P | 2006-08-29 | 2006-08-29 | |
| EP07757149.5A EP1988779B1 (en) | 2006-02-16 | 2007-02-16 | Boron-containing small molecules as anti-inflammatory agents |
| PCT/US2007/062350 WO2007095638A2 (en) | 2006-02-16 | 2007-02-16 | Boron-containing small molecules as anti-inflammatory agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02188B true ME02188B (me) | 2016-02-20 |
Family
ID=38372267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-97A ME02188B (me) | 2006-02-16 | 2007-02-16 | Mali molekuli koji sadrže boron kao antiinflamatorni agensi |
Country Status (24)
| Country | Link |
|---|---|
| US (12) | US8168614B2 (enExample) |
| EP (2) | EP1988779B1 (enExample) |
| JP (4) | JP5419466B2 (enExample) |
| KR (7) | KR20080110751A (enExample) |
| CN (2) | CN103479654B (enExample) |
| AU (1) | AU2007214421B2 (enExample) |
| BR (1) | BRPI0708051A2 (enExample) |
| CA (2) | CA2642583C (enExample) |
| CY (1) | CY1121899T1 (enExample) |
| DK (2) | DK2719388T3 (enExample) |
| ES (2) | ES2542342T3 (enExample) |
| HR (1) | HRP20150710T1 (enExample) |
| HU (2) | HUE044941T2 (enExample) |
| IL (2) | IL193230A (enExample) |
| ME (1) | ME02188B (enExample) |
| MX (2) | MX360301B (enExample) |
| NZ (1) | NZ570257A (enExample) |
| PL (2) | PL2719388T3 (enExample) |
| PT (2) | PT2719388T (enExample) |
| RS (1) | RS54108B1 (enExample) |
| RU (2) | RU2642628C2 (enExample) |
| SI (2) | SI1988779T1 (enExample) |
| WO (1) | WO2007095638A2 (enExample) |
| ZA (1) | ZA200806754B (enExample) |
Families Citing this family (129)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7767657B2 (en) | 2005-02-16 | 2010-08-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| ES2872962T3 (es) | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| RU2642628C2 (ru) * | 2006-02-16 | 2018-01-25 | Анакор Фармасьютикалз, Инк. | Бор-содержащие малые молекулы в качестве противовоспалительных средств |
| BRPI0711155A2 (pt) | 2006-05-02 | 2011-08-23 | Anacor Pharmaceuticals Inc | terapêuticos contendo boro resistentes hidroliticamente e métodos de uso |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| JO3396B1 (ar) * | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| US9523090B2 (en) | 2007-10-25 | 2016-12-20 | Revalesio Corporation | Compositions and methods for treating inflammation |
| US9745567B2 (en) | 2008-04-28 | 2017-08-29 | Revalesio Corporation | Compositions and methods for treating multiple sclerosis |
| US10125359B2 (en) | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
| JP2015178508A (ja) * | 2008-01-09 | 2015-10-08 | アナコール ファーマシューティカルズ，インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
| WO2009111676A2 (en) * | 2008-03-06 | 2009-09-11 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-inflammatory agents |
| JP5745279B2 (ja) * | 2008-01-09 | 2015-07-08 | アナコール ファーマシューティカルズ，インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
| EP3246034A1 (en) * | 2008-03-06 | 2017-11-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
| AU2009233711B2 (en) * | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| US20100256092A1 (en) * | 2008-05-12 | 2010-10-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2010027975A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| US8461336B2 (en) | 2008-09-04 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| US9493489B2 (en) | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
| WO2010045505A1 (en) * | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
| SG172040A1 (en) * | 2008-12-17 | 2011-07-28 | Anacor Pharmaceuticals Inc | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| EP2458995A1 (en) | 2009-07-28 | 2012-06-06 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
| WO2011019612A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
| WO2011019616A1 (en) | 2009-08-14 | 2011-02-17 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
| AP4039A (en) * | 2009-08-14 | 2017-02-28 | Daitao Chen | Boron-containing small molecules as antiprotozoal agents |
| US20110207701A1 (en) * | 2009-08-19 | 2011-08-25 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
| JP2013505262A (ja) * | 2009-09-17 | 2013-02-14 | バンダービルト ユニバーシティー | ｍＧｌｕＲ５ネガティブアロステリックモジュレータとしての置換ヘテロアリールアミンカルボキサミド類似体、ならびに、その形成方法および使用方法 |
| US20110124597A1 (en) * | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
| WO2011049971A1 (en) | 2009-10-20 | 2011-04-28 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
| US8461134B2 (en) * | 2009-11-11 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2011063293A1 (en) | 2009-11-20 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antihelminth agents |
| US8716478B2 (en) | 2010-01-27 | 2014-05-06 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| BR112012019120A2 (pt) | 2010-02-03 | 2016-06-28 | Infinity Pharmaceuticais Inc | forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah |
| WO2011116348A1 (en) | 2010-03-19 | 2011-09-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agent |
| JP5699030B2 (ja) * | 2010-07-05 | 2015-04-08 | Ａｘｉｓ株式会社 | エタネルセプトを含む線維筋痛症の治療剤 |
| RU2599791C2 (ru) | 2010-08-10 | 2016-10-20 | Ремпекс Фармасьютикэлз, Инч. | Циклические бороновые кислотно-эфирные производные и их использование в терапии |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ｈｔ2ｃ 작동제의 변형-방출 투여 형태 |
| DK2613788T3 (en) | 2010-09-07 | 2017-08-07 | Anacor Pharmaceuticals Inc | BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS |
| MX2013006708A (es) | 2010-12-15 | 2013-09-13 | Olatec Ind Llc | Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor. |
| US8927593B2 (en) | 2011-08-19 | 2015-01-06 | Glaxo Group Limited | Benzofuran compounds for the treatment of hepatitis C virus infections |
| WO2013033461A1 (en) | 2011-08-31 | 2013-03-07 | Rempex Pharmaceuticals, Inc. | Heterocyclic boronic acid ester derivatives and therapeutic uses thereof |
| AR088669A1 (es) | 2011-11-21 | 2014-06-25 | Lilly Co Eli | Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos |
| AR088668A1 (es) | 2011-11-21 | 2014-06-25 | Lilly Co Eli | Moleculas pequeñas que contienen boro |
| US8530452B2 (en) * | 2011-12-22 | 2013-09-10 | Micurx Pharmaceuticals, Inc. | Tricyclic boron compounds for antimicrobial therapy |
| KR102002664B1 (ko) | 2012-02-27 | 2019-07-23 | 오라텍 세라퓨틱스 엘엘씨 | 3-메틸술포닐프로피오니트릴의 제조 방법 |
| US9156858B2 (en) | 2012-05-23 | 2015-10-13 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA2875053C (en) | 2012-06-05 | 2020-07-14 | Olatec Industries Llc | Pharmaceutical composition for treating inflammation and pain |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| MX368641B (es) | 2012-06-11 | 2019-10-09 | Olatec Ind Llc | Compuestos para el tratamiento de inflamación y dolor. |
| US9114122B2 (en) | 2012-06-14 | 2015-08-25 | Olatec Industries Llc | Compounds for treating inflammation and pain |
| US8980544B2 (en) | 2012-11-27 | 2015-03-17 | The Penn State Research Foundation | Boronic and borinic acid compounds as inhibitors of sulfenic acid-containing proteins |
| US9241947B2 (en) | 2013-01-04 | 2016-01-26 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2014204045B2 (en) | 2013-01-04 | 2018-10-18 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US9101638B2 (en) | 2013-01-04 | 2015-08-11 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| KR20150103270A (ko) | 2013-01-04 | 2015-09-09 | 렘펙스 파머수티클스 인코퍼레이티드 | 보론산 유도체 및 그의 치료적 용도 |
| US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
| US8669207B1 (en) | 2013-01-30 | 2014-03-11 | Dow Agrosciences, Llc. | Compounds and compositions |
| US9585396B2 (en) | 2013-01-30 | 2017-03-07 | Agrofresh Inc. | Volatile applications against pathogens |
| US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
| AR094666A1 (es) | 2013-01-30 | 2015-08-19 | Dow Agrosciences Llc | Uso de benzoxaborolas como agentes antimicrobianos volátiles en carnes, plantas o partes de plantas |
| AP2015008638A0 (en) | 2013-02-01 | 2015-08-31 | Anacor Pharmaceuticals Inc | Boron-containing small molecules as antiprotozoal agents |
| KR101636431B1 (ko) * | 2013-07-30 | 2016-07-05 | 동아에스티 주식회사 | 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도 |
| WO2015042532A1 (en) * | 2013-09-23 | 2015-03-26 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
| US9585958B2 (en) * | 2013-09-24 | 2017-03-07 | The Regents Of The University Of California | Compositions and methods for reducing lactate levels |
| WO2015077246A1 (en) | 2013-11-19 | 2015-05-28 | Vanderbilt University | Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mglur5 |
| US9533982B2 (en) | 2014-03-20 | 2017-01-03 | Vanderbilt University | Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators |
| WO2015171398A1 (en) | 2014-05-05 | 2015-11-12 | Rempex Pharmaceuticals, Inc. | Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof |
| US10385074B2 (en) | 2014-05-05 | 2019-08-20 | Rempex Pharmaceuticals, Inc. | Synthesis of boronate salts and uses thereof |
| AU2015264418A1 (en) | 2014-05-19 | 2016-11-10 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| AU2015284307A1 (en) | 2014-07-01 | 2017-02-02 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN106459097A (zh) | 2014-07-01 | 2017-02-22 | 第三共株式会社 | 作为抗菌剂的三环苯并氧杂硼杂环戊烯类 |
| US9550778B2 (en) | 2014-10-03 | 2017-01-24 | Vanderbilt University | Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5 |
| WO2016081297A1 (en) | 2014-11-18 | 2016-05-26 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| AR103397A1 (es) * | 2015-01-13 | 2017-05-10 | Syngenta Participations Ag | Oxoborazoles microbicidas |
| BR112017014839A2 (pt) * | 2015-01-13 | 2018-06-19 | Syngenta Participations Ag | novos microbicidas |
| WO2016149393A1 (en) | 2015-03-17 | 2016-09-22 | Rempex Pharmaceuticals, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CA2981773C (en) | 2015-04-09 | 2022-03-15 | The Penn State Research Foundation | Synergistic benzoxaborole-containing anti-fungicidal composition |
| WO2017024022A1 (en) * | 2015-08-06 | 2017-02-09 | The Penn State Research Foundation | Benzoxaborole-containing coating resistant to cellulose-supportable fungus |
| WO2017093857A1 (en) * | 2015-11-30 | 2017-06-08 | Anacor Pharmaceuticals, Inc. | Topical pharmaceutical formulations for treating inflammatory-related conditions |
| US10611780B2 (en) | 2016-03-02 | 2020-04-07 | Bill And Melinda Gates Foundation | Boron-containing small molecules |
| CN109152932B (zh) | 2016-03-02 | 2021-09-28 | 比尔及梅琳达盖茨基金会 | 含硼小分子 |
| US10874679B2 (en) | 2016-03-02 | 2020-12-29 | Bill & Melinda Gates Foundation | Boron-containing small molecules |
| WO2017155879A1 (en) | 2016-03-07 | 2017-09-14 | Agrofresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
| US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
| SG11201809984PA (en) | 2016-05-09 | 2018-12-28 | Anacor Pharmaceuticals Inc | Crystal forms of crisaborole in free form and preparation method and use thereof |
| AU2017275599B2 (en) | 2016-06-03 | 2021-09-02 | Basf Se | Benzoxaborole compounds |
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| CN107759625B (zh) * | 2016-08-22 | 2020-12-29 | 药源药物化学（上海）有限公司 | 4-(1-羟基-1,3-二氢苯并[c][1,2]氧杂硼杂环戊二烯-5-基氧基)苯氰的制备方法 |
| WO2019190503A1 (en) * | 2018-03-28 | 2019-10-03 | Cove Bio Llc | Methods and compositions for treating parkinson's disease |
| GB201701583D0 (en) | 2017-01-31 | 2017-03-15 | Drug Delivery Solutions Ltd | Topical composition |
| WO2018150327A1 (en) * | 2017-02-14 | 2018-08-23 | Wavelength Enterprises Ltd | Crisaborole production process |
| US10961261B2 (en) | 2017-03-01 | 2021-03-30 | Anacor Pharmaceuticals, Inc. | Oxaborole analogs and uses thereof |
| CA3054138A1 (en) * | 2017-03-09 | 2018-09-13 | The Penn State Research Foundation | Boron-containing small molecules for inhibiting activity of a receptor-like protein tyrosine phosphatase |
| US10981939B2 (en) | 2017-05-12 | 2021-04-20 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of 4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl) oxy] benzonitrile (Crisaborole) |
| CN108864160A (zh) * | 2017-05-16 | 2018-11-23 | 苏州旺山旺水生物医药有限公司 | 含硼小分子的制备方法 |
| BR112020007138B1 (pt) | 2017-10-11 | 2023-03-21 | Qpex Biopharma, Inc | Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos |
| WO2019096113A1 (zh) * | 2017-11-14 | 2019-05-23 | 深圳市塔吉瑞生物医药有限公司 | 一种氘代的含硼的化合物及药物组合物和用途 |
| MX2020005464A (es) | 2017-11-30 | 2020-12-03 | Boragen Inc | Compuestos de benzoxaborol y formulaciones de los mismos. |
| US10329311B1 (en) * | 2017-12-21 | 2019-06-25 | Olon S.P.A. | Process for the preparation of crisaborole |
| ES2949908T3 (es) | 2018-01-09 | 2023-10-03 | Halcyon Labs Private Ltd | Proceso para la preparación de Crisaborol y sus intermedios |
| US11427603B2 (en) | 2018-03-09 | 2022-08-30 | University Of The Sciences | Protective groups and methods for protecting benzoxaboroles or oxaboroles |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| CN112424209A (zh) | 2018-04-20 | 2021-02-26 | Qpex生物制药有限公司 | 硼酸衍生物及其治疗用途 |
| CN108997394A (zh) * | 2018-06-12 | 2018-12-14 | 广州百霆医药科技有限公司 | 苯并氧杂硼杂环戊烷类化合物及其制备方法 |
| CN108659024A (zh) * | 2018-07-24 | 2018-10-16 | 武汉轻工大学 | 克立硼罗的制备方法 |
| CN112384201A (zh) * | 2018-07-31 | 2021-02-19 | Mc2疗法有限公司 | 局部组合物 |
| EP3836938A4 (en) | 2018-08-18 | 2022-05-11 | Boragen, Inc. | SOLID FORMS OF SUBSTITUTED BENZOXAZOLE AND COMPOSITIONS THEREOF |
| KR102007887B1 (ko) | 2018-10-25 | 2019-08-07 | (주)씨플렉스필름 | 회전기능을 갖는 수중 촬영장치 |
| KR102038146B1 (ko) | 2018-10-25 | 2019-11-04 | 김준희 | 밸런스 웨이트 위치 이동형 크레인을 포함하는 수중 촬영 시스템 |
| CN109456347B (zh) * | 2018-10-29 | 2021-02-05 | 安徽省庆云医药股份有限公司 | 一种克立硼罗的制备方法 |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN112174989B (zh) | 2019-07-02 | 2023-06-20 | 江西同和药业股份有限公司 | 一种克立硼罗的制备方法 |
| CN110664756B (zh) * | 2019-10-09 | 2020-11-17 | 吉林大学 | 一种小儿外伤喷雾剂及其制备方法 |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| CN111303195B (zh) * | 2020-04-07 | 2022-09-27 | 中国医学科学院放射医学研究所 | 一类含硼小分子化合物、其制备方法及应用 |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
| WO2021226208A2 (en) | 2020-05-05 | 2021-11-11 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| KR102698413B1 (ko) | 2020-05-05 | 2024-08-26 | 뉴베일런트, 아이엔씨. | 헤테로방향족 거대환식 에터 화학치료제 |
| WO2022043936A1 (en) | 2020-08-31 | 2022-03-03 | Pfizer Inc. | Methods of protecting rna |
| US11766369B1 (en) | 2020-09-30 | 2023-09-26 | Douglas Dillon | Single use protective cover for patient transport device |
| CN114685537A (zh) * | 2020-12-28 | 2022-07-01 | 南京理工大学 | 丁苯酞衍生物g-3702在制备脑缺血再灌注损伤预防和治疗药物中的应用 |
| CN113136023B (zh) * | 2021-04-25 | 2021-11-30 | 盐城海关综合技术服务中心 | 含羟甲基多孔芳香骨架的制备方法及其功能化材料和应用 |
| TW202320768A (zh) | 2021-10-01 | 2023-06-01 | 美商努法倫特公司 | 雜芳族大環醚化合物之固體形式、醫藥組成物及製備 |
| WO2023076453A1 (en) * | 2021-10-29 | 2023-05-04 | An2 Therapeutics, Inc. | Treating neuroinflammatory conditions |
| AU2023295285A1 (en) * | 2022-06-17 | 2024-12-05 | Borah, Inc. | Boron containing pyrimidine compounds, compositions comprising them, methods and uses thereof |
| GB202306663D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Combination therapy |
| CN117534695A (zh) * | 2023-11-16 | 2024-02-09 | 南京农业大学 | 含二苯(硫)醚的苯并硼唑类化合物及其制备方法与应用 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2260336A (en) | 1939-10-16 | 1941-10-28 | Dow Chemical Co | Method of preparation of organic borates |
| US3686398A (en) | 1970-07-20 | 1972-08-22 | Chevron Res | 10,9-boroxarophenanthrene as fungicides |
| GB1396904A (en) | 1972-08-11 | 1975-06-11 | Ici Ltd | Method for the control of micro-organisms |
| US4766113A (en) | 1975-10-24 | 1988-08-23 | Chapman Chemical Company | Antimicrobial compositions and methods of using same |
| US4602011A (en) | 1975-10-24 | 1986-07-22 | Chapman Chemical Company | Antimicrobial compositions and methods of using same |
| US4716035A (en) | 1985-05-24 | 1987-12-29 | The Procter & Gamble Company | Oral compositions and methods for treating gingivitis |
| US5962498A (en) * | 1986-06-11 | 1999-10-05 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity |
| US4894220A (en) | 1987-01-30 | 1990-01-16 | Colgate-Palmolive Company | Antibacterial antiplaque oral composition |
| US4919934A (en) | 1989-03-02 | 1990-04-24 | Richardson-Vicks Inc. | Cosmetic sticks |
| SG47101A1 (en) | 1992-07-31 | 1998-03-20 | Us Bioscience | Crystalline amifostine compositions and methods for the preparation and use of same |
| US5348947A (en) | 1993-05-07 | 1994-09-20 | American Cyanamid Company | Diarylboron ester and thioester fungicidal agents |
| US5348948A (en) | 1993-05-07 | 1994-09-20 | American Cyanamid Company | 2,2-diaryl-1-(oxa and thia)-2a-azonia-2-borataacenaphthene fungicidal |
| US5594151A (en) | 1994-01-28 | 1997-01-14 | Prolinx, Inc. | Phenylboronic acid complexing reagents derived from aminosalicylic acid |
| GB9411587D0 (en) | 1994-06-09 | 1994-08-03 | Zeneca Ltd | Compound, composition and use |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| GB9500856D0 (en) | 1995-01-17 | 1995-03-08 | Zeneca Ltd | Composition and use |
| WO1998024753A1 (en) | 1996-12-02 | 1998-06-11 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same |
| GB9604926D0 (en) | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| US5831046A (en) | 1996-08-05 | 1998-11-03 | Prolinx, Incorporated | Boronic acid-contaning nucleic acid monomers |
| US6413751B1 (en) | 1996-09-19 | 2002-07-02 | The Board Of Trustees Of The Leland Stanford Jr. University | DNA adenine methyltransferases and uses thereof |
| US6221640B1 (en) | 1997-05-14 | 2001-04-24 | Cubist Pharmaceuticals, Inc. | Enterococcal aminoacyl-trna synthetase proteins, nucleic acids and strains comprising same |
| DE19829947A1 (de) | 1998-07-04 | 2000-01-05 | Bayer Ag | Elektrolumineszierende Anordnungen mit Bor-Chelaten |
| US6462036B1 (en) * | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| EP1127051A2 (en) | 1998-11-06 | 2001-08-29 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| EP1155698A4 (en) | 1999-01-29 | 2003-01-15 | Nitto Kasei Co Ltd | ORGANOBORAL COMPOUNDS HAVING COCCIDIOSTAT ACTIVITY |
| CN1370170A (zh) | 1999-05-25 | 2002-09-18 | 宾夕法尼亚州研究基金会 | Dna甲基转移酶抑制剂 |
| RU2247719C2 (ru) * | 1999-07-16 | 2005-03-10 | Лео Фармасьютикал Продактс Лтд.А/С (Левенс Кемиске Фабрик Продукционсактиесельскаб) | Аминобензофеноны как ингибиторы il-1 бета и tnf-альфа, фармацевтическая композиция и способ лечения и/или профилактики воспалительных заболеваний |
| US6306628B1 (en) | 1999-08-25 | 2001-10-23 | Ambergen, Incorporated | Methods for the detection, analysis and isolation of Nascent proteins |
| EP1767629B1 (en) | 1999-08-25 | 2011-04-20 | Ambergen, Inc. | Methods for the detection, analysis and isolation of nascent proteins |
| AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| EP1246630A4 (en) | 2000-01-06 | 2007-04-18 | Marantech Holding Llc | COMPOSITIONS AND METHODS FOR PROMOTING SKIN GROWTH AND TREATING SKIN STATE |
| US6521619B2 (en) | 2000-06-29 | 2003-02-18 | Icos Corporation | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents |
| WO2002006316A2 (en) * | 2000-07-14 | 2002-01-24 | Zycos, Inc. | Alpha-msh related compounds and methods of use |
| ATE346074T1 (de) | 2000-11-30 | 2006-12-15 | Penn State Res Found | Dna methyl transferase inhibitoren |
| DE10110051C2 (de) | 2001-03-02 | 2003-07-03 | Clariant Gmbh | Verfahren zur Herstellung von Boron- und Borinsäuren |
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| DE10143979A1 (de) | 2001-09-07 | 2003-03-27 | Clariant Gmbh | Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren |
| US7217701B2 (en) | 2001-10-11 | 2007-05-15 | Katsuhiko Mikoshiba | Intracellular calcium concentration increase inhibitors |
| CN1325504C (zh) | 2002-01-10 | 2007-07-11 | 宾夕法尼亚州研究基金会 | 制备二芳基硼酸烷基酯和络合的二芳基硼酸的方法 |
| UA80131C2 (en) * | 2002-05-28 | 2007-08-27 | Dimensional Pharm Inc | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| WO2004004661A2 (en) | 2002-07-09 | 2004-01-15 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| US7446236B2 (en) | 2002-12-02 | 2008-11-04 | Solvias Ag | Catalytic hydrogenation of carbon-heteroatom double bonds |
| MXPA05006685A (es) | 2002-12-18 | 2005-12-14 | Anacor Pharmaceuticals Inc | Antibioticos que contienen complejos de acido borinico y metodos de uso. |
| US7390806B2 (en) | 2002-12-18 | 2008-06-24 | Anacor Pharmaceuticals, Inc. | Antibiotics containing borinic acid complexes and methods of use |
| US20050125852A1 (en) | 2003-05-09 | 2005-06-09 | Sugen, Inc. | Novel kinases |
| CN1829521B (zh) * | 2003-06-16 | 2011-01-26 | 安纳考尔医药公司 | 耐水解的含硼治疗剂和使用方法 |
| CN1980694B (zh) * | 2004-05-12 | 2012-09-26 | 布赖汉姆妇女医院有限公司 | 凝溶胶蛋白治疗感染的用途 |
| EP1765360B1 (en) | 2004-06-14 | 2009-11-11 | Anacor Pharmaceuticals, Inc. | Anti-viral uses of borinic acid complexes |
| AR049915A1 (es) | 2004-06-14 | 2006-09-13 | Anacor Pharmaceuticals Inc | Compuestos con contenido de boro y metodos de uso de los mismos |
| US20060111388A1 (en) | 2004-11-19 | 2006-05-25 | University Of North Texas Health Science Center At Fort Worth | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye |
| GB0501944D0 (en) | 2005-01-31 | 2005-03-09 | Univ Cambridge Tech | Compounds for use in chemical detection and/or quantitation |
| ES2872962T3 (es) * | 2005-02-16 | 2021-11-03 | Anacor Pharmaceuticals Inc | Boronoftalidas para uso terapéutico |
| US7767657B2 (en) | 2005-02-16 | 2010-08-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| JP5084717B2 (ja) | 2005-03-08 | 2012-11-28 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | キラル・ビスオキサゾリン触媒 |
| US20060251689A1 (en) | 2005-03-30 | 2006-11-09 | Astion Development A/S | Treatment or prevention of pruritus |
| US20080234229A1 (en) | 2005-08-18 | 2008-09-25 | Auspex Pharmaceuticals, Inc. | Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
| RU2642628C2 (ru) | 2006-02-16 | 2018-01-25 | Анакор Фармасьютикалз, Инк. | Бор-содержащие малые молекулы в качестве противовоспалительных средств |
| BRPI0713010A2 (pt) | 2006-06-12 | 2012-10-09 | Anacor Pharmaceuticals Inc | compostos para o tratamento de doença periodontal |
| US20070286822A1 (en) | 2006-06-12 | 2007-12-13 | Anacor Pharmaceuticals Inc. | Compounds for the Treatment of Periodontal Disease |
| KR100848491B1 (ko) | 2007-01-16 | 2008-07-28 | 영진약품공업주식회사 | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 |
| JO3396B1 (ar) | 2007-06-20 | 2019-10-20 | Anacor Pharmaceuticals Inc | جزيئات صغيرة تحتوي على البورون |
| KR100895300B1 (ko) | 2007-07-20 | 2009-05-07 | 한국전자통신연구원 | 생체신호 측정의복과 생체신호 처리시스템 |
| WO2009111676A2 (en) | 2008-03-06 | 2009-09-11 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-inflammatory agents |
| EP3246034A1 (en) | 2008-03-06 | 2017-11-22 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-inflammatory agents |
| US20100256092A1 (en) | 2008-05-12 | 2010-10-07 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| US8461336B2 (en) | 2008-09-04 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2010027975A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| WO2010045505A1 (en) | 2008-10-15 | 2010-04-22 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules as anti-protozoal agents |
| US9493489B2 (en) | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
| SG172040A1 (en) | 2008-12-17 | 2011-07-28 | Anacor Pharmaceuticals Inc | Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol |
| EP2458995A1 (en) | 2009-07-28 | 2012-06-06 | Anacor Pharmaceuticals, Inc. | Trisubstituted boron-containing molecules |
| US8461134B2 (en) | 2009-11-11 | 2013-06-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
| US8716478B2 (en) | 2010-01-27 | 2014-05-06 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
-
2007
- 2007-02-16 RU RU2013152132A patent/RU2642628C2/ru not_active Application Discontinuation
- 2007-02-16 MX MX2013015092A patent/MX360301B/es unknown
- 2007-02-16 HR HRP20150710TT patent/HRP20150710T1/hr unknown
- 2007-02-16 EP EP07757149.5A patent/EP1988779B1/en active Active
- 2007-02-16 BR BRPI0708051-4A patent/BRPI0708051A2/pt not_active Application Discontinuation
- 2007-02-16 PT PT13179945T patent/PT2719388T/pt unknown
- 2007-02-16 WO PCT/US2007/062350 patent/WO2007095638A2/en not_active Ceased
- 2007-02-16 EP EP13179945.4A patent/EP2719388B1/en active Active
- 2007-02-16 PL PL13179945T patent/PL2719388T3/pl unknown
- 2007-02-16 KR KR1020087022631A patent/KR20080110751A/ko not_active Ceased
- 2007-02-16 NZ NZ570257A patent/NZ570257A/en unknown
- 2007-02-16 CA CA2642583A patent/CA2642583C/en active Active
- 2007-02-16 SI SI200731663T patent/SI1988779T1/sl unknown
- 2007-02-16 CN CN201310283871.4A patent/CN103479654B/zh active Active
- 2007-02-16 KR KR1020137025594A patent/KR20130120552A/ko not_active Ceased
- 2007-02-16 CN CN2007800133393A patent/CN101420854B/zh active Active
- 2007-02-16 KR KR1020147035518A patent/KR101622870B1/ko active Active
- 2007-02-16 ES ES07757149.5T patent/ES2542342T3/es active Active
- 2007-02-16 JP JP2008555528A patent/JP5419466B2/ja active Active
- 2007-02-16 KR KR1020157027015A patent/KR20150113219A/ko not_active Ceased
- 2007-02-16 SI SI200732111T patent/SI2719388T1/sl unknown
- 2007-02-16 AU AU2007214421A patent/AU2007214421B2/en active Active
- 2007-02-16 RS RS20150474A patent/RS54108B1/sr unknown
- 2007-02-16 DK DK13179945.4T patent/DK2719388T3/da active
- 2007-02-16 KR KR1020157000589A patent/KR20150013941A/ko not_active Ceased
- 2007-02-16 DK DK07757149.5T patent/DK1988779T5/en active
- 2007-02-16 PT PT77571495T patent/PT1988779E/pt unknown
- 2007-02-16 KR KR1020147013817A patent/KR20140082842A/ko not_active Ceased
- 2007-02-16 US US11/676,120 patent/US8168614B2/en active Active
- 2007-02-16 HU HUE13179945 patent/HUE044941T2/hu unknown
- 2007-02-16 MX MX2008010381A patent/MX2008010381A/es active IP Right Grant
- 2007-02-16 PL PL07757149T patent/PL1988779T3/pl unknown
- 2007-02-16 RU RU2008137086/15A patent/RU2508113C2/ru active
- 2007-02-16 HU HUE07757149A patent/HUE025048T2/en unknown
- 2007-02-16 KR KR1020177001541A patent/KR101819869B1/ko active Active
- 2007-02-16 ME MEP-2015-97A patent/ME02188B/me unknown
- 2007-02-16 CA CA2933994A patent/CA2933994A1/en not_active Abandoned
- 2007-02-16 ES ES13179945T patent/ES2728455T3/es active Active
-
2008
- 2008-08-04 IL IL193230A patent/IL193230A/en active IP Right Grant
- 2008-08-04 ZA ZA2008/06754A patent/ZA200806754B/en unknown
-
2012
- 2012-04-23 US US13/453,682 patent/US8501712B2/en active Active
-
2013
- 2013-07-30 US US13/954,770 patent/US9029353B2/en active Active
- 2013-08-23 JP JP2013173486A patent/JP2013253097A/ja active Pending
-
2015
- 2015-04-13 JP JP2015082026A patent/JP2015147795A/ja active Pending
- 2015-04-16 US US14/688,581 patent/US9682092B2/en active Active
- 2015-09-21 IL IL241792A patent/IL241792B/en active IP Right Grant
-
2016
- 2016-07-14 JP JP2016139202A patent/JP6266708B2/ja active Active
-
2017
- 2017-05-18 US US15/599,203 patent/US20170258819A1/en not_active Abandoned
-
2019
- 2019-02-01 US US16/265,006 patent/US20190160081A1/en not_active Abandoned
- 2019-05-14 CY CY20191100519T patent/CY1121899T1/el unknown
- 2019-05-31 US US16/427,621 patent/US20190282594A1/en not_active Abandoned
- 2019-10-08 US US16/595,633 patent/US20200046745A1/en not_active Abandoned
-
2020
- 2020-02-13 US US16/789,777 patent/US20200179418A1/en not_active Abandoned
- 2020-08-27 US US17/004,047 patent/US20210000847A1/en not_active Abandoned
-
2022
- 2022-07-20 US US17/869,351 patent/US20230008130A1/en not_active Abandoned
-
2024
- 2024-07-08 US US18/765,739 patent/US20240358728A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150710T1 (hr) | Male molekule koje sadrže bor kao protu-upalni agensi | |
| HRP20231381T1 (hr) | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu | |
| JP2009531292A5 (enExample) | ||
| JP2022541514A5 (enExample) | ||
| HRP20230502T1 (hr) | Inhibitori trpc6 | |
| HRP20250340T1 (hr) | Terapijske upotrebe deuteriranih derivata lanifibranora | |
| JP2008546714A5 (enExample) | ||
| Zhao et al. | Sliding mode control combined with extended state observer for an ankle exoskeleton driven by electrical motor | |
| HRP20171296T1 (hr) | Derivati benzonitrila kao inhibitori kinaze | |
| JP2021500403A5 (enExample) | ||
| JP2020536917A5 (enExample) | ||
| JP2011513476A5 (enExample) | ||
| HRP20240355T1 (hr) | 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja | |
| CN101693697A (zh) | 哌嗪衍生物和它们作为治疗剂的用途 | |
| HRP20190135T1 (hr) | 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk | |
| JP2020519654A5 (enExample) | ||
| EA201892790A1 (ru) | Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний | |
| HRP20201416T1 (hr) | Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2 | |
| JP2006510676A5 (enExample) | ||
| JP2008521829A5 (enExample) | ||
| JP2014508731A5 (enExample) | ||
| JP2010535215A5 (enExample) | ||
| JP2016540749A5 (enExample) | ||
| CA2797533A1 (en) | Compounds that modulate intracellular calcium | |
| JP2013193825A5 (enExample) |